vs
雅培（ABT）与奥尼兰姆制药（ALNY）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是奥尼兰姆制药的10.4倍（$11.5B vs $1.1B）。奥尼兰姆制药净利率更高（17.0% vs 15.5%，领先1.5%）。奥尼兰姆制药同比增速更快（84.9% vs 4.4%）。雅培自由现金流更多（$2.6B vs $140.3M）。过去两年奥尼兰姆制药的营收复合增速更高（49.0% vs 7.2%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
奥尼兰姆制药是美国生物制药企业，2002年成立，总部位于马萨诸塞州剑桥市，专注于研发及商业化针对基因明确疾病的RNA干扰（RNAi）疗法，2016年入选福布斯「100家最具创新力成长企业」榜单。
ABT vs ALNY — 直观对比
营收规模更大
ABT
是对方的10.4倍
$1.1B
营收增速更快
ALNY
高出80.5%
4.4%
净利率更高
ALNY
高出1.5%
15.5%
自由现金流更多
ABT
多$2.5B
$140.3M
两年增速更快
ALNY
近两年复合增速
7.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $1.1B |
| 净利润 | $1.8B | $186.4M |
| 毛利率 | 57.0% | 75.6% |
| 营业利润率 | 19.6% | 12.0% |
| 净利率 | 15.5% | 17.0% |
| 营收同比 | 4.4% | 84.9% |
| 净利润同比 | -80.8% | 322.6% |
| 每股收益（稀释后） | $1.01 | $1.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTALNY
| Q4 25 | $11.5B | $1.1B | ||
| Q3 25 | $11.4B | $1.2B | ||
| Q2 25 | $11.1B | $773.7M | ||
| Q1 25 | $10.4B | $594.2M | ||
| Q4 24 | $11.0B | $593.2M | ||
| Q3 24 | $10.6B | $500.9M | ||
| Q2 24 | $10.4B | $659.8M | ||
| Q1 24 | $10.0B | $494.3M |
净利润ABTALNY
| Q4 25 | $1.8B | $186.4M | ||
| Q3 25 | $1.6B | $251.1M | ||
| Q2 25 | $1.8B | $-66.3M | ||
| Q1 25 | $1.3B | $-57.5M | ||
| Q4 24 | $9.2B | $-83.8M | ||
| Q3 24 | $1.6B | $-111.6M | ||
| Q2 24 | $1.3B | $-16.9M | ||
| Q1 24 | $1.2B | $-65.9M |
毛利率ABTALNY
| Q4 25 | 57.0% | 75.6% | ||
| Q3 25 | 55.4% | 84.2% | ||
| Q2 25 | 56.4% | 81.6% | ||
| Q1 25 | 56.9% | 88.2% | ||
| Q4 24 | 55.0% | 82.7% | ||
| Q3 24 | 55.8% | 83.6% | ||
| Q2 24 | 55.6% | 89.8% | ||
| Q1 24 | 55.2% | 89.0% |
营业利润率ABTALNY
| Q4 25 | 19.6% | 12.0% | ||
| Q3 25 | 18.1% | 29.5% | ||
| Q2 25 | 18.4% | -2.1% | ||
| Q1 25 | 16.3% | 3.0% | ||
| Q4 24 | 17.4% | -17.7% | ||
| Q3 24 | 17.5% | -15.4% | ||
| Q2 24 | 16.1% | 7.4% | ||
| Q1 24 | 13.9% | -8.8% |
净利率ABTALNY
| Q4 25 | 15.5% | 17.0% | ||
| Q3 25 | 14.5% | 20.1% | ||
| Q2 25 | 16.0% | -8.6% | ||
| Q1 25 | 12.8% | -9.7% | ||
| Q4 24 | 84.1% | -14.1% | ||
| Q3 24 | 15.5% | -22.3% | ||
| Q2 24 | 12.5% | -2.6% | ||
| Q1 24 | 12.3% | -13.3% |
每股收益（稀释后）ABTALNY
| Q4 25 | $1.01 | $1.44 | ||
| Q3 25 | $0.94 | $1.84 | ||
| Q2 25 | $1.01 | $-0.51 | ||
| Q1 25 | $0.76 | $-0.44 | ||
| Q4 24 | $5.26 | $-0.66 | ||
| Q3 24 | $0.94 | $-0.87 | ||
| Q2 24 | $0.74 | $-0.13 | ||
| Q1 24 | $0.70 | $-0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $1.7B |
| 总债务越低越好 | $12.9B | — |
| 股东权益账面价值 | $52.1B | $789.2M |
| 总资产 | $86.7B | $5.0B |
| 负债/权益比越低杠杆越低 | 0.25× | — |
8季度趋势，按日历期对齐
现金及短期投资ABTALNY
| Q4 25 | $8.9B | $1.7B | ||
| Q3 25 | $7.7B | $1.5B | ||
| Q2 25 | $7.3B | $1.1B | ||
| Q1 25 | $6.8B | $1.0B | ||
| Q4 24 | $8.0B | $966.4M | ||
| Q3 24 | $7.8B | $1.1B | ||
| Q2 24 | $7.2B | $968.5M | ||
| Q1 24 | $6.7B | $681.9M |
总债务ABTALNY
| Q4 25 | $12.9B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $14.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABTALNY
| Q4 25 | $52.1B | $789.2M | ||
| Q3 25 | $51.0B | $233.9M | ||
| Q2 25 | $50.6B | $250.6M | ||
| Q1 25 | $48.8B | $115.4M | ||
| Q4 24 | $47.7B | $67.1M | ||
| Q3 24 | $39.8B | $32.4M | ||
| Q2 24 | $39.3B | $-3.1M | ||
| Q1 24 | $38.8B | $-219.3M |
总资产ABTALNY
| Q4 25 | $86.7B | $5.0B | ||
| Q3 25 | $84.2B | $4.9B | ||
| Q2 25 | $84.0B | $4.6B | ||
| Q1 25 | $81.4B | $4.2B | ||
| Q4 24 | $81.4B | $4.2B | ||
| Q3 24 | $74.4B | $4.2B | ||
| Q2 24 | $73.0B | $4.0B | ||
| Q1 24 | $72.5B | $3.8B |
负债/权益比ABTALNY
| Q4 25 | 0.25× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.30× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $163.6M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | $140.3M |
| 自由现金流率自由现金流/营收 | 22.9% | 12.8% |
| 资本支出强度资本支出/营收 | 6.0% | 2.1% |
| 现金转化率经营现金流/净利润 | 1.87× | 0.88× |
| 过去12个月自由现金流最近4个季度 | $7.4B | $465.4M |
8季度趋势，按日历期对齐
经营现金流ABTALNY
| Q4 25 | $3.3B | $163.6M | ||
| Q3 25 | $2.8B | $325.1M | ||
| Q2 25 | $2.0B | $153.7M | ||
| Q1 25 | $1.4B | $-118.3M | ||
| Q4 24 | $2.9B | $-94.7M | ||
| Q3 24 | $2.7B | $43.7M | ||
| Q2 24 | $2.0B | $124.2M | ||
| Q1 24 | $1.0B | $-81.5M |
自由现金流ABTALNY
| Q4 25 | $2.6B | $140.3M | ||
| Q3 25 | $2.3B | $313.0M | ||
| Q2 25 | $1.5B | $139.4M | ||
| Q1 25 | $933.0M | $-127.3M | ||
| Q4 24 | $2.1B | $-103.8M | ||
| Q3 24 | $2.1B | $39.5M | ||
| Q2 24 | $1.4B | $116.1M | ||
| Q1 24 | $627.0M | $-94.5M |
自由现金流率ABTALNY
| Q4 25 | 22.9% | 12.8% | ||
| Q3 25 | 20.2% | 25.1% | ||
| Q2 25 | 13.9% | 18.0% | ||
| Q1 25 | 9.0% | -21.4% | ||
| Q4 24 | 19.6% | -17.5% | ||
| Q3 24 | 20.2% | 7.9% | ||
| Q2 24 | 13.8% | 17.6% | ||
| Q1 24 | 6.3% | -19.1% |
资本支出强度ABTALNY
| Q4 25 | 6.0% | 2.1% | ||
| Q3 25 | 4.4% | 1.0% | ||
| Q2 25 | 4.5% | 1.8% | ||
| Q1 25 | 4.7% | 1.5% | ||
| Q4 24 | 6.6% | 1.5% | ||
| Q3 24 | 5.2% | 0.8% | ||
| Q2 24 | 5.1% | 1.2% | ||
| Q1 24 | 4.0% | 2.6% |
现金转化率ABTALNY
| Q4 25 | 1.87× | 0.88× | ||
| Q3 25 | 1.70× | 1.29× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABT
暂无分部数据
ALNY
| TTR | $858.3M | 78% |
| Rare | $136.4M | 12% |
| GIVLAARI | $56.3M | 5% |
| Collaborative Arrangement | $40.9M | 4% |
| ONPATTRO | $12.0M | 1% |
